These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 23530499)
1. Understanding XPO1 target networks using systems biology and mathematical modeling. Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499 [TBL] [Abstract][Full Text] [Related]
2. Nucleo-cytoplasmic transport as a therapeutic target of cancer. Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752 [TBL] [Abstract][Full Text] [Related]
3. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834 [TBL] [Abstract][Full Text] [Related]
5. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391 [TBL] [Abstract][Full Text] [Related]
6. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials. Lai C; Xu L; Dai S Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482 [TBL] [Abstract][Full Text] [Related]
7. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918 [TBL] [Abstract][Full Text] [Related]
8. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282 [TBL] [Abstract][Full Text] [Related]
9. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export. Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897 [TBL] [Abstract][Full Text] [Related]
10. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315 [TBL] [Abstract][Full Text] [Related]
11. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568 [TBL] [Abstract][Full Text] [Related]
12. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209 [TBL] [Abstract][Full Text] [Related]
13. XPO1-dependent nuclear export as a target for cancer therapy. Azizian NG; Li Y J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143 [TBL] [Abstract][Full Text] [Related]
14. The hippo kinase STK38 ensures functionality of XPO1. Martin AP; Camonis JH Cell Cycle; 2020 Nov; 19(22):2982-2995. PubMed ID: 33017560 [TBL] [Abstract][Full Text] [Related]
15. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096 [TBL] [Abstract][Full Text] [Related]
16. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma. Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108 [TBL] [Abstract][Full Text] [Related]
17. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859 [No Abstract] [Full Text] [Related]